- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (236)
- Breast Cancer (712)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (158)
- Colon Cancer (166)
- Colorectal Cancer (106)
- Endocrine Tumor (4)
- Esophageal Cancer (40)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (2)
- Kidney Cancer (124)
- Leukemia (352)
- Liver Cancer (50)
- Lung Cancer (290)
- Lymphoma (286)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (102)
- Myelodysplastic Syndrome (64)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (176)
- Pancreatic Cancer (172)
- Parathyroid Disease (2)
- Penile Cancer (16)
- Pituitary Tumor (6)
- Prostate Cancer (146)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (58)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (32)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (8)
- Biostatistics (2)
- Blood Donation (16)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (220)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (870)
- Research (402)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (600)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (180)
- Treatment (1758)
Why a protein causes tumor growth in brain, but not other organs
BY Ron Gilmore
2 minute read | Published November 11, 2015
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on November 11, 2015
It’s no surprise that people enjoy warm places like Hawaii, but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it’s affected by the microenvironments of certain bodily organs to which it travels.
Scientists at MD Anderson have found that PTEN is regulated by different organs. For patients with brain metastases, this is not good, as PTEN in cells is shut off in the brain. Surprisingly, PTEN is restored once cells migrate to other organs.
It’s a discovery that may be important for developing effective new anti-metastasis therapies of particular importance for advanced-stage brain cancer patients. The study findings were published last month in Nature.
“Development of life-threatening cancer metastasis requires that tumor cells adapt to and evolve within drastically different microenvironments of metastatic sites,” said Dihua Yu, M.D., Ph.D., deputy chair of the Department of Molecular and Cellular Oncology. “Yet it is unclear when and how tumor cells acquire the essential traits in a foreign organ’s microenvironment that lead to successful metastasis.”
Yu’s study found that metastatic brain tumor cells that have experienced PTEN loss have PTEN levels restored once they leave the brain. They determined that the “reversible” PTEN loss is induced by micro RNAs (miRNAs) from astrocytes located in the brain and spinal cord. Astrocytes, so called for their star shape, secrete exosomes that contain PTEN-targeting miRNAs and transfer PTEN-targeting miRNAs inter-cellularly to tumor cells via exosomes. Exosomes are tiny, virus-sized particles. MiRNAs are non-coding molecules known to play a role in regulation of gene expression.
The team also found that the PTEN loss in brain tumor cells led to an increased secretion of a cytokine known as CCL2, which recruits brain cells known as microglial cells to metastatic tumors. This enhances tumor cell growth and protects tumor cells from cell death, which leads to life-threatening brain metastases.
Read more about the study on MD Anderson’s website.
Topics
Translational Research